Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Juno and Fate partner in new CAR/TCR deal

Executive Summary

Fate Therapeutics Inc. granted Juno Therapeutics Inc. exclusive worldwide rights to IP surrounding its hematopoietic cell programming platform, which will be used to identify small-molecule modulators for Juno’s genetically engineered chimeric antigen receptor (CAR) and T-cell receptor (TCR) cancer immunotherapies.
Deal Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
    • Vaccines
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Includes Equity
    • Includes Royalty or Profit Split Information
    • Intra-Biotech Deal
    • Includes Contract

Related Companies